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RAS proteins work as GDP-GTP binary switches and regulate cytoplasmic sig-
nalling networks that are able to control several cellular processes, playing an essential
role in signal transduction pathways involved in cell growth, differentiation and survival
so that overacting RAS signalling can lead to cancer. One of the hardest challenges to
face is the design of mutation-selective therapeutic strategies. In this work, a G12D
mutated farnesylated GTP bound Kirsten RAt Sarcoma (KRAS) protein has been
simulated at the interface of a DOPC/DOPS/cholesterol model anionic cell membrane.
A specific long-lasting salt bridge connection between farnesyl and the hypervariable
region of the protein has been identified as the main mechanism responsible of the
binding of oncogenic farnesylated KRAS-4B to the cell membrane. Free-energy land-
scapes allowed us to characterise local and global minima of KRAS-4B binding to the
cell membrane revealing the main pathways between anchored and released states.
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RAS proteins are small guanosine-triphosphatase (GTPase) species that can be activated
or de-activated by guanosine-diphosphate (GDP)-guanosine-triphosphate (GTP) switching[1].
Consequently, the interaction of GTP with RAS and their surroundings is an issue of high
interest[2]. As surface proteins anchored in the inner leaflet of the cell membrane (i.e. at the
cytoplasm), RAS species are normally in the inactive state and they are activated following an
incoming signal from their upstream regulators. RAS proteins play an essential role in signal
transduction pathways which ultimately turn on genes involved in cell growth, differentiation
and survival, eventually leading to cancer[3, 4, 5]. Conventionally, mutant RAS is consid-
ered to be defective in GAP-mediated GTP hydrolysis, which results in an accumulation of
constitutive GTP-bound RAS in cells. Missense gain-of-function mutations in all three RAS
genes are found in 27% of all human cancers, with 98% of the mutations at one of three mu-
tational hotspots: G12, G13 and Q61. It has been found that HRAS is the least frequently
mutated RAS isoform in human cancers (4%), whereas KRAS is the predominantly mutated
isoform (85%), followed by NRAS (11%). However, it is unclear how these mutations affect
KRAS association with biological membranes[6]. Consequently, we have chosen the specific
mutated G12D KRAS-4B as our target oncogenic protein. KRAS has two splice variants,
KRAS-4A and KRAS-4B, the latter being found at higher concentration levels[7], in partic-
ular in lung, colorectal, and pancreatic cancer cells[8, 9, 10, 11]. These insights suggests the
importance of fully understanding the regulation of oncogenic KRAS-4B activity when bind-
ing on the membrane. KRAS-4B has a highly conserved N-terminal catalytic domain (CD,
residues 1-166) and a flexible C-terminal 22-25-amino acid-long, hypervariable region (HVR,
residues 167-185)[12]. Apart from different HVR sequences, KRAS-4B is distinguished by its
unique HVR post-translational modification (PTM). Usually, HVR lipidation promote RAS
anchoring in the plasma membrane. HVR preferentially binds the membrane in the liquid
phase and spontaneously inserts its terminal farnesyl (FAR) moiety into the loosely packed
phospholipid bilayers[7]. Accumulating evidence indicates that demethylated and farnesy-
lated KRAS-4B (KRAS-4B-Far) could play an important role in the signalling pathways
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that happen on the inner leaflet of the membrane bilayers. KRAS-4B-Far has been reported
to be able to be transferred to bind the inner plasma membrane (PM) leaflet. According
to Ntai et al. 91% of the mutant KRAS-4B and 51% of wild-type KRAS-4B proteins in
certain colorectal tumor samples have been found to be of the KRAS-4B-Far isoform[13].
Nevertheless, the effects of KRAS-4B-Far on downstream signalling have yet to be deter-
mined. While most efforts have been focused on characterisation of methylated KRAS-4B
(KRAS-4B-FMe) binding to the PM, study on KRAS-4B-Far is still an emerging area of
research. According to Barcelo et al.[14], phosphorylation at Ser-181 of oncogenic KRAS is
required for tumor growth so that in the present work we have chosen to phosphorylate at
Ser-181 to model the main mutated oncogenic KRAS-4B protein under study.
In this Letter we shall provide essential information in order to gain precise understanding
of the effects of oncogenic mutations on the localisation of wild-type and oncogenic KRAS-
4B proteins and on their eventual mechanisms to anchor the cell. According to Nussinov
et al.[15], the two major pathways in oncogenic RAS-driven proliferation can be promoted
when KRAS is membrane-anchored. Furthermore, understanding the structural specifics of
KRAS-4B in its GTP-bound form will help to design oncogenic KRAS-4B inhibitors[16].
So, methods of reducing or weakening the interactions between oncogenic KRAS-4B and the
membrane with a good knowledge of the structural mechanisms at the atomic level will be
a promising target for anticancer drug discovery[17]. On its own, genomics sequence data
may not provide the entire information to the oncologist for the selection of targets. Fur-
ther, the GTP affinity of KRAS-4B is reported to be extremely high, with a dissociation
constant of around 10 mol/L [18], yet the corresponding binding free-energy hypersurface
has been poorly explored. The free-energy landscape (FEL) idea is compelling because it
enables us to map many possible conformations which the protein could populate along the
different levels of free-energies so that recommendations for treatments might derive from
the corresponding FEL, producing further insight into the underlying biological mechanisms
and fostering molecular targeting in a significant way[19]. RAS association with membranes
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is not a one-way street and they undergo a cycle of delivery to the PM followed by return to
endomembranes for recycling[20]. In this work we have applied well-tempered metadynamics
to reveal the affinity of GTP to KRAS-4B and lipids and to obtain the binding free-energy
barriers of the process of anchoring of FAR at membrane bilayers from a free-energy per-
spective, especially for membranes with relatively high contents of cholesterol.
The process of post-translational modifications required to allow KRAS-4B to function
properly in cells is represented in Fig. 1: Firstly the prenylation reaction, catalysed by cy-
tosolic farnesyltrasferase (FTase) or geranylgeranyltransferase (GGTase), proceeds through
the addition of an isoprenyl group to the Cys-185 side chain. Then farnesylated KRAS-4B
is ready for further processing: hydrolysis, catalysed by the endopeptidase enzyme called
RAS-converting enzyme 1 (RCE1), during the process the VIM motif (HVR tail composed
of three amino-acids: valine-isoleucine-methionine) of the C-terminal Cys-185 is lost in step
2. Later KRAS-4B is transferred to the endoplasmic reticulum for carboxymethylation at
the carboxyl terminus of Cys-185 catalysed by isoprenylcysteine carboxyl methyltransferase
(ICMT), forming a reversible ester bond. The outcome of these modifications is the far-
nesylated and methylated KRAS-4B (KRAS-4B-FMe). The reversible ester bond can go
through decarboxymethylation, catalysed by prenylated/polyisoprenylated methylated pro-
tein methyl esterases (PMPEases) giving rise to a farnesylated and demethylated KRAS-4B
(KRAS-4B-Far) which is the product of step 2 and reactant of step 3. This reversible re-
action can modulate the equilibrium of methylated/demethylated KRAS-4B population in
tumors and consequently can impact downstream signalling, protein-protein interactions, or
protein-lipid interactions [21].
After establishing the reliability of the systems studied in the present work using molec-
ular dynamics (MD), very successful to describe a wide variety of molecular setups at the
all-atom level, including complex biological systems[22, 23, 24, 25] and metadynamics simu-
lations, able to compute free energy barriers with high precision (see Supporting Information,
SI, including a summary table of all simulations carried out), we have analysed the structure
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carboxyl methyltransferase (ICMT), forming a reversible ester bond. The outcome
of these modifications is the farnesylated and methylated KRas-4B (KRas-4B-FMe).
The reversible ester bond can go through decarboxymethylation, catalyzed by Preny-
lated/polyisoprenylated methylated protein methyl esterases (PMPEases) giving rise
to a farnesylated and demethylated KRas-4B (KRas-4B-Far) which is the product of
step 2 and reactant of step 3. This reversible reaction can modulate the equilibrium of
methylated/demethylated KRas-4B population in tumors and consequently can impact



























Fig. 1.4 PTMs steps of KRas-4B: prenylation, hydrolysis, carboxymethylation and
decarboxymethylation.
One of the best known reversible PTMs in HVR is phosphorylation[134, 136, 137].
There are two sites (Ser-171 and Ser-181) within HVR that could be phosphorylated.
Phosphorylation involves the addition of phosphate (PO3≠4 ) group to the side chain of
the amino acid serine, then the phosphorylated serine is obtained. Phosphorylation at
Ser-181 operates a farnesyl-electrostatic switch that reduces but does not completely
inhibit membrane-association and clustering of KRas-4B, leading to redistribution to
the cytoplasm and endomembranes[133, 138, 139], whereas, phosphorylation at Ser-171
is less vital for its function[139]. Functionally, phosphorylation of KRas-4B can have
either a negative[140, 141] or positive[139, 142] regulatory e ect on the tumor cell
growth, depending on the conditions[135]. For instance, from an MD simulation of
the HVR peptide with the farnesyl group (FAR) at Cys-185 of KRas-4B in two types
Figure 1: Process of post-translational modifications responsible to the formation of KRAS-
4B-Far and KRAS-4B-FMe.
of KRAS at the interface of the membrane by means of a series of radial distribution func-
tions (RDF) between selected atomic ites (as described in Figs. S2, S5 and S6). Being the
most relevant, RDF of GTP and FAR are shown in Fig. 2. Additional RDF are reported in
Fig. S7 (r lated to CD) a d Fig. S8 (rela ed to HVR).
Firstly, hydrogen-bonds (HB) between GTP and active sites of specific aminoacids of the
CD have been observ d ( op of Fig.2). A clear first coordination shell located around 1.75
Å shall be essentially attributed to HB between selected atom sites. The typical signature
of oxygen-hydrogen HB in lipid cell membranes is a maximum located at 1.8 Å [26]. For
oncogenic KRAS-4B systems, GTP tends to bind the CD of the protein through HB, whereas
no HB between GTP and lipids have been observed. From the results reported here, we can
observe that GTP prefers binding to the CD of oncogenic KRAS-4B proteins regardless of
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Figure 2: Top three plots: Selected RDF for active atoms of GTP with selected sites of
the CD and active oxygen atoms of head groups of lipids (’O2L’). ’Hgtp’ and ’Ogtp’ represent
hydrogen and oxygen atoms from phosphate group of GTP. Bottom four plots: Selected RDF
related to selected sites of FAR. Here Ofar and Hfar correspond to atomic sites belonging to
farnesylated KRAS-4B, whereas Ofme stands for oxygen atoms of methylated KRAS-4B.
carboxymethylation at site Cys-185 before anchoring to the membrane leaflet. In particular,
for wild-type KRAS-4B-Far, HB between GTP and the CD are much stronger (∼ 15-fold)
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than HB between GTP and lipids. However, in the wild-type system GTP is mostly located
at the interface of the membrane, close to the CD of KRAS-4B. Especially strong interactions
observed between GTP and CD of KRAS-4B-FMe indicate less efficient nucleotide exchange
for this mutant. To further analyse the effect of the side chain of CD, calculations were
performed revealing that CD is able to associate head groups of lipids, which proves that
CD of KRAS-4B plays a role in binding to bilayers in all cases. In the corresponding RDF
(Fig. S7), when the two selected oxygen and hydrogen sites are ionised the location of the
first shell is usually at distances shorter than 1.8 Å . The contribution of the first shell is
from a so-called salt bridge[27, 28], which coupling was reported to be of general importance
to the stability and function of proteins. A salt bridge has two components: a hydrogen
bond and an electrostatic ionic interaction. Very common in proteins are those between
the anionic carboxylate (RCOO−) of aspartic or glutamic acid and the cationic ammonium
(RNH+3 ) from lysine or the guanidinium (RNHC(NH2)
+
2 ) of arginine. Of all non-covalent
interactions, salt bridges are among the strongest[29]. In the particular case of KRAS-4B,
it has been recently observed that salt bridges can be formed between the protein and PIP2
species[30, 31]. Here we report that the first shell of RDF due to salt bridges between
OCD and Hdops is located at 1.65 Å for the three systems (the two oncogenic and the wild-
type species of the protein). Nevertheless, it has been shown that HB between the cationic
ammonium (RNH+3 ) from lysine of CD of KRAS-4B-FMe and anionic oxygen atoms from
DOPS is much stronger than for demethylated KRAS-4B isoforms. Consecutively, RDF
related to HVR are displayed in Fig. S8. We have found that HVR is able to form HB
and salt bridges with CD, membrane lipids and PHOS. Carboxylmethylation and mutations
show their influence on the interactions of HVR with DOPS and PHOS (panels D and F).
Whereas the first shell is located at 1.65 Å , the salt bridge between OHV R and Hdops is much
weaker for oncogenic KRAS-4B-FMe, when comparing with the demethylated case. After
phosphorylation (as shown in Fig. S4), oncogenic KRAS-4B proteins (by means of Ophos)
are able to form stable salt bridges with hydrogen atoms of cationic ammonium from the
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HVR (HHV R). However, for wild-type KRAS-4B-Far only weak HB exit between HHV R and
some oxygen atom from the side chain of site Ser-181. As it was pointed out in Refs. [32, 33]
our results suggest that CD and HVR have a significant role in binding to the PM, although
engaging to the membrane in different ways.
We have investigated meaningful RDF of active sites of FAR with PHOS, CD, and lipids.
We obtained (panel D, bottom of Fig.2) that in the oncogenic KRAS-4B-Far system FAR
forms strong and long-lasting salt bridges with DOPS, through negatively charged Ofar
interacting strongly with the positive charged Hdops of DOPS. In the case of the oncogenic
KRAS-4B-FMe, HB are found (panel A) between the carbonyl oxygen of the ester group of
Cys-181 (Ofme), which is weakly basic, and the positive hydrogen of the hydroxyl group of
Tyr from CD (HTyr−CD). FAR can also interact with cholesterol (panel B) through typical
HB and with DOPS through strong salt bridge for wild-type KRAS-4B-Far, which guarantees
that the GTP-bound wild-type KRAS-4B-Far could anchor into anionic membrane bilayers.
However, the most remarkable fact is seen in panel C (bottom of Fig.2). Only in the oncogenic
KRAS-4B-Far long-lasting salt bridges have been located between oxygen and hydrogen
atoms from FAR and PHOS, indicating that anchoring of FAR in the oncogenic KRAS-
4B-Far possesses a large stability provided by the permanent binding of the FAR-PHOS
pair. Consequently, the anchoring mechanism described here is playing a key role in order
to reach the stability required for oncogenic KRAS proteins to be able to become functional,
remaining attached to the inner surface of the plasma membrane through its farnesylated
and poylcationic C-terminus[34].
In the snapshot reported in Fig. 3, we described the long-lasting and strong salt bridges
existing between active sites of FAR and PHOS, only for the oncogenic KRAS-4B-Far protein.
O1Pphos and O2Pphos could shift to form salt bridge with Hfar, but only one of them could
interact with Hfar hauling the typical HB distance, with one of them favored by Hfar because
of the conformational restrictions in the structure even though both of them share one





Figure 3: Snapshot of long-lasting salt bridges indicated as black lines of dashes between
FAR and PHOS of the oncogenic KRAS-4B-Far. The atoms represented here are: carbon
(cyan), oxygen (red), hydrogen (white), nitrogen (blue) and phosphorus (brown). Hydrogen
bonds are represented in black dashed lines.
Hphos, Hfar, O1Pphos/O2Pphos, the nitrogen, and two carbons of FAR form a very stable
7-membered ring endowing the oncogenic KRAS-4B-Far to get such a specific structure in
its tail able to allow the anchoring to PM or reacting with other proteins in vivo. Finally,
in order to monitor the interactions between FAR and PHOS for the oncogenic KRAS-4B-
Far system, we displayed the time evolution of selected atom-atom distances in Fig. S9
regarding the strong salt bridge observed in panel C (bottom of Fig.2), where we see that
the anchoring mechanism described here is fully stable throughout a simulation span of 500
ns. In summary, the finding or design of drugs able to break the long-lasting bonds between
FAR and PHOS could be a key factor for the release of oncogenic proteins such as KRAS-
4B from its anchoring to the membrane towards the internal regions of the cell, eventually
becoming harmless.
At the atomic level, the four main configurations corresponding to two stable states of
the wild-type KRAS-4B-Far and to the main stable states of oncogenic KRAS-4B-Far and
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KRAS-4B-FMe obtained from MD simulations are illustrated in Fig. 4. We report in Fig.
S10 the Z-axis (normal to the XY instantaneous plane of the membrane) positions of center
of FAR and GTP from the center of lipids (z = 0) using the second half of the 1000 ns
simulations. After thorough inspection of Fig. S10 and Fig. 4, together with the averaged
values reported in Table 1, we report a list of relevant findings in SI.
Configuration 1: Configuration 2:
Configuration 3: Configuration 4:
wt. KRAS4B-Far wt. KRAS4B-Far
onc. KRAS4B-Far onc. KRAS4B-FMe
Figure 4: Four preferential configurations of the three KRAS-4B-membrane systems obtained
from MD simulations at the all-atom level.
Table 1: Averaged values of z-locations (in nm) of FAR, HVR, CD, and GTP
for KRAS-4B systems. Values of locations of FAR from configurations 1 and 2
have been provided for the wild-type case. Estimated errors in parenthesis.
Systems FAR GTP HVR CD
wt. KRAS-4B-Far 3.9(0.48)/1.73(0.23) 2.40(0.17) 3.93(0.25) 4.48(0.13)
onc. KRAS-4B-Far 1.37(0.18) 5.16(0.60) 3.56(0.19) 4.70(0.28)
onc. KRAS-4B-FMe 3.82(0.36) 5.07(0.94) 3.84(0.24) 4.70(0.41)
In order to elucidate the joint effect of phosphorylation and G12D mutation on the
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energetic characteristics of the binding of KRAS-4B in cell membranes, the FEL of wild-
type and oncogenic demethylated KRAS-4B-Far proteins have been computed using the
well-tempered metadynamics method. A full study of the convergence of the simulations is
reported in SI. Transition states between stable minima are not reported, but they could be
easily located with the method employed here[35]. Free-energy landscapes are dynamic and
conformational states can change in response to intra- and extramolecular events[36, 37],
such as the localisations of FAR and GTP. Given the specific interest of the oncogenic and
wild-type KRAS-4B-Far proteins in the anchoring of RAS proteins in cell membranes, we
have computed two-dimensional (2D) FEL for the corresponding two sets of proteins bound
to the anionic membrane composed of DOPC:DOPS:cholesterol (28:7:15) considered above.
The hypersurfaces are reported in Fig. 5 and each (meta-)stable state can be indexed by a
pair of CV. Several regions with clear minima are present in the two FEL. Since the range of
CV space represented in Fig. 5 is rather wide, we will focus especially in the characterisation
of free-energy barriers between the particular states of localisations of FAR and GTP in the
FEL in the region close to one leaflet of the membrane.
Given that the present 2D FEL include a wide variety of (meta-)stable states, methods
able to trace the minimum free-energy path (MFEP) between stable states with high accu-
racy are highly needed. MFEP can be determined by iteratively refine a pathway connecting
stable states that converges to the minimum free-energy trajectories between them. MFEP
could also be obtained through the Path Collective Variables description coupled with meta-
dynamics[38]. Alternatively to biased-MD simulation methods, certain spontaneous binding
events can also be achieved through extensive standard MD simulations, for example, run-
ning for µs to ms simulation time[39, 40]. From MFEP we can extract information associated
to the most probable trajectories in the CV space followed by the system involving between
(meta-)stable states and it also allows us the determination of local and global transition
states. In this way, we have traced the MFEP along the free-energy landscape using the
guidelines sketched in SI by means of the R-package metadynminer[41]. Two MFEP have
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been depicted in Fig. 5 where the global minimum is set to zero. The coordinates of minimum
free-energy paths are reported in Table S5.
Figure 5: Left: 2D free-energy landscapes F(gtp, far) (kJ/mol) for the oncogenic KRAS-4B-
Far system. Several stable and meta-stable configurations (A, B, C, D, E) are indicated.
Right: 2D free-energy landscapes F(gtp, far) (kJ/mol) of wild-type KRAS-4B system. Stable
and meta-stable configurations (A, B, C, D) are indicated. All MFEP between two selected
basins are depicted in purple and the relevant coordinates have been reported in Table S5.
For oncogenic KRAS-4B-Far protein (left of Fig. 5), the most stable state (global min-
imum) and four more meta-stable states have been revealed and their coordinates shown
in Table S6. The stable or meta-stable configurations that oncogenic KRAS-4B-Far may
adopt when bound to the anionic membrane are as follows: in state A, FAR anchors into
the ”internal” regions of the membrane when GTP is close to the interface and binds the
CD moiety as well; in state B, FAR anchors into the ”internal” regions of membrane when
GTP only binds the CD moiety; in state C FAR has been released off the membrane, but
GTP is still bound at the interface; in state D, FAR is solvated by water molecules and
GTP only binds the membrane interface and in state E, GTP reaches out further away from
the lipidic region and is solvated by the aqueous solution, while FAR keeps being anchored
into the membrane. The main findings obtained for the oncogenic case are: (1) While FAR
is anchored to the membrane, GTP dissociates from stable state A then binds to the CD
moiety (state B), requiring to cross a free-energy barrier of 27.04 kJ/mol. The final state is
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essentially represented by configuration 3 of Fig. 4; (2) The difference between states C and
D is most likely due to the location of HVR. HVR may bind the head groups of lipids (state
C) and it can be solvated in the aqueous region (state E). The estimated free-energy barrier
∆F between states C and D is of 17.20 kJ/mol; (3) We estimated a high free-energy barrier
of 42.44 kJ/mol from state A to state C, which explains that for oncogenic KRAS-4B-Far,
the affinity of FAR to the anionic membrane is extremely high and (4) ∆F for the transition
between states B and E has been estimated to be of 27.5 kJ/mol, corresponding to the energy
needed to get the release of GTP from its association from the CD of the protein to water
solvation, which explains the high affinity of GTP to CD in the oncogenic KRAS-4B-Far.
Correspondingly, in the case of the FEL of wild-type KRAS-4B-Far protein, two global
stable states (A, B) and two more meta-stable states (C, D) have been identified and their
coordinates are shown in Table S7 whereas MFEP is shown in Fig.5. In this case the main
features are: (1) When FAR is bound to the membrane (state B), a barrier of 10.76 kJ/mol
should be crossed by FAR shifting to the global stable state A while GTP keeps bound to
the CD, but apart from the interface; (2) Shifting from state B to state C (FAR anchored
in a deeper position and GTP closer to the interface) can be realised if a free-energy barrier
of 6.69 kJ/mol is surmounted; (3) When the system shifts its state between A and D (i.e.
FAR solvated in the aqueous region), the crossing of a free-energy barrier of 20.10 kJ/mol
corresponds to the energy needed for the HVR to be released from the anionic membrane and
(4) There are several meta-stable states when GTP locates ∼2 nm away from the membrane
center, indicating the existence of multiple configurations when GTP is around head groups
of lipids, which may play a role in KRAS-4B-Far signal transduction and interactions with
other proteins in vivo. As a direct connection to experimental measures[42], it is possible to
project the 2D surfaces integration out a single CV. Our numerical results are exhaustively
reported in SI (with free-energy profiles reported in Fig.S16).
To summarise the main findings of the work, KRAS-4B belongs to a family of small
GTPase that regulate cell growth, differentiation and survival which is frequently mu-
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tated in cancers such as in lung, colon and pancreatic ones. Given that the structural
mechanisms at the atomic level of KRAS-4B-membrane association are unknown, we con-
ducted MD simulations of three systems of GTP-bound KRAS-4B (oncogenic KRAS-4B-
FMe and KRAS-4B-Far, wild-type KRAS-4B-Far) bound to cell membranes constituted by
DOPC/DOPS/cholesterol including KCl solution at 310.15 K and at the fixed pressure of 1
atm. Each oncogenic KRAS-4B protein contains two mutations: G12D and phosphorylation
at its Ser-181 site. KRAS-4B association with the PM requires the penetration of FAR into
the membrane and interactions of HVR with lipids in order to allow KRAS-4B a proper
localisation in the membrane. We observed that for wild-type KRAS-4B-Far, demethylated
Cys-185 allows spontaneous insertion and release of FAR into the anionic membrane bilayer
without much difficulty. Conversely, oncogenic KRAS-4B-Far keeps anchored to the mem-
brane and staying in its active site in order to bind upstream regulators and downstream
effectors. Further, oncogenic KRAS-4B-FMe stays in an auto-inhibited state in which the
HVR is sandwiched between the effector binding site of the CD and the membrane, blocking
signal transduction pathways. Interactions such as HB and long-lived salt bridges between
different active sites of GTP, the CD, the HVR and lipids have been revealed that to play
a central role in the stabilisation of KRAS-4B membrane proteins. In particular, only in
the oncogenic KRAS-4B-Far case long-lived salt bridges have been located between oxygen
and hydrogen atoms from FAR and PHOS, providing large stability to the anchoring of the
KRAS-4B-Far into the PM. We believe this is the key for the permanent association be-
tween the oncogenic protein and the inner layer of cell membranes. Further, the information
reported in this work could be very valuable to the development of farnesyltransferase in-
hibitors as anti-cancer agents[43]. Among the two chosen mutations to generate the oncogenic
KRAS-4B proteins, we have observed that PHOS has important influence on the behavior of
oncogenic KRAS-4B proteins, together with the effect of PTM such as carboxymethylation,
which always play a role in the localisation of KRAS-4B at the PM. The reported free-energy
profiles of GTP binding to anionic membrane bilayers gave us first-hand information about
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FEL of GTP-bound wild-type/oncogenic KRAS-4B-Far binding to anionic membrane sys-
tems. We have located global and local stable states of the two systems that have been chosen
to elucidate the joint effect of PHOS and G12D on the KRAS-4B-membrane binding. Our
results indicate that for GTP-bound oncogenic KRAS-4B-Far it exists a free-energy barrier
of 42.44 kJ/mol for the departure of FAR from the PM, which explains the large stability of
the FAR moiety of oncogenic KRAS-4B-Far at the anionic membrane. This fully corresponds
to the findings reported from MD simulations. Correspondingly, a barrier of 10.76 kJ/mol is
likely to be crossed for FAR of wild-type KRAS-4B-Far shifting from anchoring to the PM to
being solvated by water while GTP keeps bound to the CD (shift between configurations 1
and 2 of Fig. 4). We have estimated a free-energy barrier of 20.10 kJ/mol when FAR of the
wild-type case shifts from ∼4 nm to 6 nm away from the membrane center, corresponding
to the energies needed for the HVR dissociating from the anionic membrane.
We conducted MD simulations of model anionic (neutral) cell membranes constituted by
DOPC (56%), DOPS (14%) and cholesterol (30%) in aqueous ionic solution for the three
KRAS-4B isoforms with sequences represented in Fig. S1. The technical details of the
simulations are reported in SI. After equilibrating properly the system in the two cases of
wild-type/oncogenic KRAS-4B-Far from a 1 µs run for each system, we switched to run
another 1.1 µs of well-tempered metadynamics simulations to perform Gibbs free-energy
calculations of KRAS-4B binding at anionic phospholipid membrane bilayers, starting from
the last configuration of MD simulations. Among the wide variety of methods proposed
to obtain free-energy landscapes of multidimensional systems[2, 44, 45, 46, 47, 48, 49, 50,
51, 52], we have chosen well-tempered metadynamics, a method able to efficiently explore
free-energy surfaces of complex systems using multiple reaction coordinates in complex sys-
tems[53, 54, 55, 56, 57]. Well-tempered metadynamics simulations were performed using the
joint GROMACS/2018.3-PLUMED2 tool[58]. Full technical details are reported in SI. Data
sets needed to reproduce the two metadynamics simulations reported in the present work
can be found in the PLUMED-NEST web page: https://www.plumed-nest.org/eggs/20/028/
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from the public repository of the PLUMED consortium.
Supporting Information Available
Full computational details are reported on: (1) system structure and composition; (2) molec-
ular dynamics simulation setups for the full KRAS-4B/DOPC/DOPS/cholesterol membrane
system; (3) supplementary results on structure, area per lipid and thickness of the mem-
brane as well as radial distribution functions related to the catalytic domain and hypervari-
able regions of the protein; (4) well-tempered metadynamics simulations that lead to the
construction of the 2D free-energy surfaces as a function of the class of protein, focusing
especially on their stability and convergence; (5) technical details about the calculation of
minimum free-energy paths. This material is available free of charge via the Internet at
http://pubs.acs.org/.
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Greenman, I. Varela, M.-L. Lin, G.R. Ordóñez, G.R. Bignell, and et al. “A compre-
hensive catalogue of somatic mutations from a human cancer genome”. In: Nature
463.7278 (2010), pp. 191–196.
[11] M. Pek, S.M.J.M. Yatim, Y. Chen, J. Li, M. Gong, X. Jiang, F. Zhang, J. Zheng, X.
Wu, and Q. Yu. “Oncogenic KRAS-associated gene signature defines co-targeting of
CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer”. In: Oncogene
36.35 (2017), pp. 4975–4986.
[12] K. Koera, K. Nakamura, K. Nakao, J. Miyoshi, K. Toyoshima, T. Hatta, H. Otani, A.
Aiba, and M. Katsuki. “K-ras is essential for the development of the mouse embryo”.
In: Oncogene 15.10 (1997), pp. 1151–1159.
[13] I. Ntai, L. Fornelli, C.J. DeHart, J.E. Hutton, P.F. Doubleday, R.D. LeDuc, A.J.
van Nispen, R.T. Fellers, G. Whiteley, E.S. Boja, and et al. “Precise characteriza-
tion of KRAS4b proteoforms in human colorectal cells and tumors reveals muta-
tion/modification cross-talk”. In: Proceedings of the National Academy of Sciences
115.16 (2018), pp. 4140–4145.
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